BioPharma

Here’s a look at natural product drug discovery 2.0

  • by

Plant-based drug discovery may be tens of thousands of years old, but in 2021, it feels exciting, rich, and full of potential. Companies are rapidly building scalable databases with hundreds of thousands of unique chemicals and their links to biological signatures.

The winners of INVEST Pitch Perfect are…..

  • by

The finalists across health IT, biopharma, medical devices, diagnostics, and health services tracks were judged on criteria that included: completeness of overall plan, business idea, market opportunity, revenue model, and founder(s) experience.

Vertex to pay CRISPR Therapeutics $900M for bigger share of gene-editing alliance

  • by

Vertex Pharmaceuticals is amending its collaboration with CRISPR Therapeutics, paying $900 million now for chance to grab a bigger share of a gene-editing therapy’s profits later—if the treatment is approved. Clinical trials evaluating the CRISPR-based therapy are underway in sickle cell disease and beta thalassemia.

3 changes coming to drug pricing

  • by

No matter if Democrats or Republicans are running the show in Washington, here are three solid bets for pharma companies to plan for in the changing drug-pricing landscape

How to build a diverse innovation team (and why it’s critical)

  • by

Why start with innovation? Because it’s where the products, tools, solutions, and ideas that will change the status quo are born. Without diversity of thought, experience, and perspective, the end result of innovation only serves those already at the table.

Decentralized clinical trials are opening the drug development pipeline

  • by

With the emergence of smart and connected devices and technologies, CROs and life sciences organizations are able to more easily perform decentralized, virtual clinical trials. Now, industry leaders are on a mission to make the practice of administering decentralized clinical trials the norm.

5 AI lessons from pharma world learned during Covid-19

  • by

With the increased reliance on digital technologies, pharma companies’ outreach to healthcare providers needs to be thoughtful, efficient, and respectful. An AI-driven, omnichannel strategy makes this possible by giving every member of customer-facing teams visibility across communications.

Bristol Myers Squibb SVP Ho Sung Cho highlights legacy and ongoing research in protein degradation  [Sponsored]

  • by

Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and… Read More »Bristol Myers Squibb SVP Ho Sung Cho highlights legacy and ongoing research in protein degradation  [Sponsored]

AstraZeneca updates Covid-19 vaccine data, now showing 76% efficacy

  • by

AstraZeneca’s latest efficacy data for its Covid-19 vaccine are down slightly from the 79% it previously reported. The most recent data will form the basis of an application for emergency use authorization, which the company still expects to file with the FDA in coming weeks.

In MedCity Pivot podcast, biopharma researcher talks about protein degradation, recent success tied to Covid-19 [Sponsored]

  • by

Ho Sung Cho, senior vice president of Biodiscovery Therapeutics at Bristol Myers Squibb, talks about lessons learned from drug discovery, recent success tied to Covid-19, and how the company is leveraging its expertise in protein degradation to develop novel therapies for blood cancers, solid tumors… Read More »In MedCity Pivot podcast, biopharma researcher talks about protein degradation, recent success tied to Covid-19 [Sponsored]

AstraZeneca’s Covid-19 vaccine data may have ‘outdated information,’ NIH cautions

  • by

Federal health authorities say safety observers are concerned AstraZeneca did not release complete information about the efficacy of its Covid-18 vaccine. The company responded by saying its data were from a pre-specified analysis and it will provide the most up to date efficacy data within… Read More »AstraZeneca’s Covid-19 vaccine data may have ‘outdated information,’ NIH cautions

Antibody testing can improve efficiency in limited vaccine supply

  • by

Given our current limited supply, the threat of variant spread, and availability of higher quality antibody test kits, policymakers ought to update their vaccine guidance for those who had Covid and incorporate recent research findings on immunity and vaccine efficacy.

How Covid-19 is changing rare diseases research

  • by

While Covid has made many aspects of living with a rare disease more difficult, it has inspired policies and techniques that could help rare disease research progress more smoothly both during and after the pandemic.

The year to come in life sciences safety and regulatory practices

  • by

The life sciences industry will move toward more agile capabilities for regulatory operations and regulators toward an accelerated approval pathway in support of clinical studies, drawing from lessons learned during the pandemic around global collaboration.

Startup banks on immune-system memory to tackle cancer

  • by

Loki Therapeutics is advancing research that leverages the immune system’s ability to recall childhood vaccinations and direct it against cancer. The company’s lead therapy candidate could enter phase 1 clinical trials this year.

What is the MedCity INVEST Pitch Perfect experience like?

  • by

The INVEST Pitch Perfect contest is part of our INVEST conference April 19-23, which will be hosted online due to Covid-19, and includes five tracks for startups: biopharma, medical devices, diagnostics, health IT and health services. Read more on how to apply.

Study: Biotech no riskier for investors

  • by

Despite lower sales, lack of profits and heavy R&D spending, biotech companies that went public between 1997 and 2016 reached similar market caps as non-biotech companies, according to an academic study.

Prescient Healthcare Group to Partner with Bridgepoint Development Capital

  • by

The partnership will further enhance the depth, breadth and value of services for Prescient’s pharmaceutical and biotech clients. LONDON, January 21, 2021: Prescient Healthcare Group (Prescient), a global product strategy advisory firm serving the pharmaceutical and biotech industries, announced today that Bridgepoint Development Capital, part… Read More »Prescient Healthcare Group to Partner with Bridgepoint Development Capital

Key takeaways from BioNTech CEO’s JPM presentation

  • by

Ugur Sahin presented a sweeping vision of the company’s goal to become a next-generation immunotherapy company leveraging the messenger RNA platform technology that has won it acclaim and financial returns during the Covid-19 pandemic.

Can we warp-speed antibiotic development? 

  • by

Advocates, industry leaders and legislators have come to a consensus about the scope and urgency of the crisis related to inadequate development of antibiotics. They are calling for legislative fixes to protect public health.

Walmart pharmacies fueled opioid crisis, DOJ lawsuit claims

  • by

The Justice Department has sued Walmart for fanning the flames of the opioid crisis through its network of pharmacies, claiming that the retailer knowingly filled thousands of illegitimate opioid prescriptions. But Walmart says the lawsuit is “misguided.”

INVEST Precision Medicine Pitch Perfect winner spotlight: TrialSpark

  • by

Judges picked TrialSpark as the winner on the life sciences track of the pitch competition at MedCity’s virtual precision medicine conference. While the company is focused on improving clinical trials for others, it hopes eventually to bring drugs of its own to market.

How Verily plans to use $700M in new funding

  • by

Alphabet and other investors poured $700 million in funding into Verily last week. The company, which is Alphabet’s life sciences subsidiary, plans to pour some of the funds into supporting Covid-19 vaccine studies and programs for businesses.

FDA gives nod to Moderna vaccine for Covid-19

  • by

The company’s vaccine is the second approved for emergency use by the FDA. It is expected to pose fewer logistical challenges than the first, which was developed by Pfizer and BioNTech.

FDA gives emergency OK to Pfizer and BioNTech vaccine

  • by

The vaccine was developed in record time, a big scientific accomplishment, even though the agency’s move follows an unusual level of pressure from President Trump’s White House, renewing concerns that politics drove the vaccine process even as the first doses are shipped.

AI offers promise but faces barriers in drug development

  • by

Inertia is a barrier as is the traditional split between the clinical and the data-driven spheres of drug development. While smaller firms have an edge in bridging the gap, big pharma will eventually get there, said panelists at the INVEST conference session.

Which startups will present at MedCity INVEST Precision Medicine Pitch Perfect?

  • by

Among the areas of interest for companies presenting at Pitch Perfect at INVEST Precision Medicine are clinical stroke detection, making medical research more inclusive, using technology to accelerate the pace of clinical trials, developing more patient friendly drug delivery systems for reconstitutable drugs, and more.

Level Ex pitches gaming as a tool for reaching doctors

  • by

Interactive, cloud-based video games are designed to tackle pharma’s current challenge: engaging doctors virtually during a pandemic. But the tools are likely to outlive the circumstances in which they were born.

CVS to distribute newly authorized antibody therapy

  • by

CVS Health’s infusion business will participate in a pilot to administer a recently authorized monoclonal antibody treatment to prevent patients from getting seriously ill with Covid-19. But data about the treatment, bamlanivimab, is mixed, and supply is limited.

French startup lands $8.7M to advance microbiome therapies

  • by

Founded in 2014, MaaT Pharma is pushing two therapies through clinical trials that are designed improve survival for patients with blood cancers and other diseases. Despite high-profile hiccups, the field of microbiome therapy remains attractive to investors.

7 Best Practices for Third-Party Risk Management in the Pharmaceutical Industry

  • by

Dr. Aleksandr Yampolskiy, CEO of SecurityScorecard, The globalization of the pharmaceutical industry has forced pharma companies to outsource, increasing their reliance on third-party vendors and suppliers. As this supply chain grows in complexity, companies find themselves grappling with a growing amount of cyber risk.  A… Read More »7 Best Practices for Third-Party Risk Management in the Pharmaceutical Industry

Important questions about Pfizer’s Covid-19 vaccine

  • by

News of positive results from Pfizer’s Covid-19 vaccine is heartening but historically, important scientific announcements about vaccines are made through peer-reviewed medical research papers that have undergone extensive scrutiny about study design, results and assumptions, not through company press releases.

String of FDA approvals gives momentum to liquid biopsies

  • by

Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.

The precision medicine conference you don’t want to miss

  • by

The summit gathers directors through the C-suite from across life science and healthcare sectors to discuss new developments in precision medicine, investment trends, and how health IT, diagnostics and biopharma technology are being used to improve outcomes.

To avoid crisis, pharma must address costs

  • by

Scrutiny of drug prices will continue whether Trump or Biden wins. But pharma can take steps to address critics and cut costs before they reach a crisis point, according to a panel of industry experts.

Bayer paying up to $4B for gene therapy pioneer AskBio

  • by

The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson’s and congestive heart failure.